Journal of Antimicrobial Chemotherapy, Vol 40, 59-66, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
MW Climo, SM Markowitz, DS Williams, CG Hale-Cooper and GL Archer
The activity of methicillin, oxacillin, vancomycin, imipenem and FK037
against 106 isolates of staphylococci was assessed using a microbroth
dilution method with low (10(5) cfu/mL) and high (10(7) cfu/mL) inoculum
sizes. Overall, FK037, an oxime-type cephem antibiotic, was as active as
imipenem, but less active than vancomycin (MIC90s 25, 25 and 6.25 mg/L,
respectively) at the lower inoculum. Efficiency of plating experiments were
also performed to characterize phenotypic expression of resistance to
FK037, imipenem and methicillin. Five of 24 isolates and 18 of 24 isolates
contained subpopulations resistant to FK037 and imipenem, respectively. In
a rabbit model of endocarditis, FK037 was equally effective as other
antibiotics tested in the treatment of methicillin-sensitive Staphylococcus
aureus infection. In the treatment of endocarditis due to a homotypic
methicillin-resistant S. aureus, FK037 and vancomycin were the most active
antibiotics. The presence of subpopulations resistant to imipenem and
FK037, as demonstrated by efficiency of plating and high inoculum MIC
testing, did not correlate with antibiotic effectiveness in the rabbit
model of endocarditis. Cultures of vegetation material following treatment
with imipenem and FK037 demonstrated a lower frequency of organisms
resistant to FK037 when compared with imipenem. Thus FK037 shows in-vitro
and in-vivo activity against some methicillin-resistant staphylococcal
species.
ORIGINAL ARTICLES
Comparison of the in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species
Department of Medicine, McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Kiri, G. Archer, and M. W. Climo Combinations of Lysostaphin with {beta}-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis Antimicrob. Agents Chemother., June 1, 2002; 46(6): 2017 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Finan, G. L. Archer, M. J. Pucci, and M. W. Climo Role of Penicillin-Binding Protein 4 in Expression of Vancomycin Resistance among Clinical Isolates of Oxacillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3070 - 3075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Climo, K. Ehlert, and G. L. Archer Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1431 - 1437. [Abstract] [Full Text]
|
|
|
|
|
|
D. Jonas, I. Engels, C. Friedhoff, B. Spitzmuller, F. D. Daschner, and U. Frank Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila J. Antimicrob. Chemother., February 1, 2001; 47(2): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Climo, R. L. Patron, and G. L. Archer Combinations of Vancomycin and beta -Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1747 - 1753. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Patron, M. W. Climo, B. P. Goldstein, and G. L. Archer Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1754 - 1755. [Abstract] [Full Text]
|
|
|
|
|
|
A. Georgopoulos, A. Buxbaum, and W. Graninger Efficacy of {beta}-lactam and inhibitor combinations in a diffusion chamber model in rabbits J. Antimicrob. Chemother., April 1, 1999; 43(4): 497 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Climo, R. L. Patron, B. P. Goldstein, and G. L. Archer Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis Antimicrob. Agents Chemother., June 1, 1998; 42(6): 1355 - 1360. [Abstract] [Full Text]
|
|